[{"id":"d9ca2d5a-9151-4957-8ac9-e89e48ab0b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03706326","created_at":"2021-01-18T18:09:39.373Z","updated_at":"2024-07-02T16:37:06.033Z","phase":"Phase 1/2","brief_title":"CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer","source_id_and_acronym":"NCT03706326","lead_sponsor":"The First Affiliated Hospital of Guangdong Pharmaceutical University","biomarkers":" PD-1","pipe":" | ","alterations":" MUC1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 09/28/2021","primary_completion_date":" 09/28/2021","study_txt":" Completion: 09/28/2021","study_completion_date":" 09/28/2021","last_update_posted":"2018-10-16"},{"id":"e9a7e7b6-1a5e-486e-8b08-7dd3db167ff3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03525782","created_at":"2021-01-17T17:27:01.690Z","updated_at":"2024-07-02T16:37:10.716Z","phase":"Phase 1/2","brief_title":"Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC","source_id_and_acronym":"NCT03525782","lead_sponsor":"The First Affiliated Hospital of Guangdong Pharmaceutical University","biomarkers":" PD-1","pipe":" | ","alterations":" MUC1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anti-MUC1 CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2018-05-16"}]